1
|
Bagheri M, van Nostrum CF, Kok RJ, Storm G, Hennink WE, Heger M. Utility of Intravenous Curcumin Nanodelivery Systems for Improving In Vivo Pharmacokinetics and Anticancer Pharmacodynamics. Mol Pharm 2022; 19:3057-3074. [PMID: 35973068 PMCID: PMC9450039 DOI: 10.1021/acs.molpharmaceut.2c00455] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
![]()
Curcumin nanoformulations for intravenous injection have
been developed
to offset poor absorption, biotransformation, degradation, and excessive
clearance associated with parenteral delivery. This review investigates
(1) whether intravenous nanoformulations improve curcumin pharmacokinetics
(PK) and (2) whether improved PK yields greater therapeutic efficacy.
Standard PK parameters (measured maximum concentration [Cmax], area under the curve [AUC], distribution volume
[Vd], and clearance [CL]) of intravenously
administered free curcumin in mice and rats were sourced from literature
and compared to curcumin formulated in nanoparticles, micelles, and
liposomes. The studies that also featured analysis of pharmacodynamics
(PD) in murine cancer models were used to determine whether improved
PK of nanoencapsulated curcumin resulted in improved PD. The distribution
and clearance of free and nanoformulated curcumin were very fast,
typically accounting for >80% curcumin elimination from plasma
within
60 min. Case-matched analysis demonstrated that curcumin nanoencapsulation
generally improved curcumin PK in terms of measured Cmax (n = 27) and AUC (n = 33), and to a lesser extent Vd and
CL. However, when the data were unpaired and clustered for comparative
analysis, only 5 out of the 12 analyzed nanoformulations maintained
a higher relative curcumin concentration in plasma over time compared
to free curcumin. Quantitative analysis of the mean plasma concentration
of free curcumin versus nanoformulated curcumin did not reveal an
overall marked improvement in curcumin PK. No correlation was found
between PK and PD, suggesting that augmentation of the systemic presence
of curcumin does not necessarily lead to greater therapeutic efficacy.
Collapse
Affiliation(s)
- Mahsa Bagheri
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands
| | - Cornelus F van Nostrum
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands
| | - Robbert Jan Kok
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands
| | - Gert Storm
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands
| | - Wim E Hennink
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands
| | - Michal Heger
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands.,Jiaxing Key Laboratory for Photonanomedicine and Experimental Therapeutics, Department of Pharmaceutics, College of Medicine, Jiaxing University, Jiaxing, Zhejiang 314001, PR China
| |
Collapse
|
2
|
Hocking A, Tommasi S, Sordillo P, Klebe S. The Safety and Exploration of the Pharmacokinetics of Intrapleural Liposomal Curcumin. Int J Nanomedicine 2020; 15:943-952. [PMID: 32103948 PMCID: PMC7023862 DOI: 10.2147/ijn.s237536] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2019] [Accepted: 01/17/2020] [Indexed: 12/16/2022] Open
Abstract
Background Malignant pleural effusion (MPE) is the accumulation of fluid in the pleural cavity as a result of malignancies affecting the lung, pleura and mediastinal lymph nodes. Curcumin, a compound found in turmeric, has anti-cancer properties that could not only treat MPE accumulation but also reduce cancer burden. To our knowledge, direct administration of curcumin into the pleural cavity has never been reported, neither in animals nor in humans. Purpose To explore the compartmental distribution, targeted pharmacokinetics and the safety profile of liposomal curcumin following intrapleural and intravenous administration. Methods Liposomal curcumin (16 mg/kg) was administered into Fischer 344 rats by either intrapleural injection or intravenous infusion. The concentration of curcumin in plasma and tissues (lung, liver and diaphragm) were measured using ultra-performance liquid chromatography-mass spectrometry (UPLC-MS). Blood and tissues were examined for pathological changes. Results No pleural or lung pathologies were observed following intrapleural liposomal curcumin administration. Total curcumin concentration peaked 1.5 hrs after the administration of intrapleural liposomal curcumin and red blood cell morphology appeared normal. A red blood cells abnormality (echinocytosis) was observed immediately and at 1.5 hrs after intravenous infusion of liposomal curcumin. Conclusion These results indicate that liposomal curcumin is safe when administered directly into the pleural cavity and may represent a viable alternative to intravenous infusion in patients with pleural-based tumors.
Collapse
Affiliation(s)
- Ashleigh Hocking
- Department of Anatomical Pathology, Flinders University, Adelaide, SA, Australia
| | - Sara Tommasi
- Department of Clinical Pharmacology, Flinders University, Adelaide, SA, Australia
| | | | - Sonja Klebe
- Department of Anatomical Pathology, Flinders University, Adelaide, SA, Australia.,Department of Surgical Pathology, SA Health, Flinders Medical Centre, Bedford Park, SA, Australia
| |
Collapse
|
3
|
Greil R, Greil-Ressler S, Weiss L, Schönlieb C, Magnes T, Radl B, Bolger GT, Vcelar B, Sordillo PP. A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc ™) in patients with locally advanced or metastatic cancer. Cancer Chemother Pharmacol 2018; 82:695-706. [PMID: 30074076 PMCID: PMC6132848 DOI: 10.1007/s00280-018-3654-0] [Citation(s) in RCA: 68] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2018] [Accepted: 07/21/2018] [Indexed: 12/14/2022]
Abstract
PURPOSE This study was conducted to investigate the safety and tolerability of increasing doses of liposomal curcumin in patients with metastatic cancer. Investigations of anti-tumor activity and of the pharmacokinetics of curcumin were secondary objectives. METHODS In this phase I, single-center, open-label study in patients with metastatic tumors, liposomal curcumin was administered as a weekly intravenous infusion for 8 weeks. Dose escalation was started at 100 mg/m2 over 8 h and the dose increased to 300 mg/m2 over 6 h. RESULTS 32 patients were treated. No dose-limiting toxicity was observed in 26 patients at doses between 100 and 300 mg/m2 over 8 h. Of six patients receiving 300 mg/m2 over 6 h, one patient developed hemolysis, and three other patients experienced hemoglobin decreases > 2 g/dL without signs of hemolysis. Pharmacokinetic analyses revealed stable curcumin plasma concentrations during infusion followed by rapid declines to undetectable levels after the infusion. Anti-tumor activity by RECIST V1.1 was not detected. Significant tumor marker responses and transient clinical benefit were observed in two patients. CONCLUSION 300 mg/m2 liposomal curcumin over 6 h was the maximum tolerated dose in these heavily pretreated patients, and is the recommended starting dose for anti-cancer trials.
Collapse
Affiliation(s)
- Richard Greil
- IIIrd Medical Department, Paracelsus Medical University Salzburg, Müllner Hauptstraße 45, 5020, Salzburg, Austria.
- Salzburg Cancer Research Institute, Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT), Salzburg, Austria.
- Cancer Cluster Salzburg, Salzburg, Austria.
| | - Sigrun Greil-Ressler
- IIIrd Medical Department, Paracelsus Medical University Salzburg, Müllner Hauptstraße 45, 5020, Salzburg, Austria
- Salzburg Cancer Research Institute, Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT), Salzburg, Austria
| | - Lukas Weiss
- IIIrd Medical Department, Paracelsus Medical University Salzburg, Müllner Hauptstraße 45, 5020, Salzburg, Austria
- Salzburg Cancer Research Institute, Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT), Salzburg, Austria
| | - Charlotte Schönlieb
- IIIrd Medical Department, Paracelsus Medical University Salzburg, Müllner Hauptstraße 45, 5020, Salzburg, Austria
- Salzburg Cancer Research Institute, Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT), Salzburg, Austria
| | - Teresa Magnes
- IIIrd Medical Department, Paracelsus Medical University Salzburg, Müllner Hauptstraße 45, 5020, Salzburg, Austria
- Salzburg Cancer Research Institute, Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT), Salzburg, Austria
| | - Bianca Radl
- IIIrd Medical Department, Paracelsus Medical University Salzburg, Müllner Hauptstraße 45, 5020, Salzburg, Austria
- Salzburg Cancer Research Institute, Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT), Salzburg, Austria
| | - Gordon T Bolger
- Nucro-Technics, 2000 Ellesmere Road, Unit 16, Scarborough, ON, Canada
| | - Brigitta Vcelar
- Polymun Scientific Immunbiologische Forschung GmbH, Klosterneuburg, Austria
| | | |
Collapse
|
4
|
Bange E, Timlin C, Kabel C, Svoboda J, Roeker L, Mato AR. Evidence for and Against Green Tea and Turmeric in the Management of Chronic Lymphocytic Leukemia. CLINICAL LYMPHOMA, MYELOMA & LEUKEMIA 2018; 18:e421-e426. [PMID: 30007569 PMCID: PMC7397615 DOI: 10.1016/j.clml.2018.06.021] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/30/2018] [Accepted: 06/19/2018] [Indexed: 12/17/2022]
Abstract
Complementary and alternative medicine (CAM) is a diverse group of medical and health care systems, practices, and products that are not generally considered part of conventional medicine. Chronic lymphocytic leukemia (CLL) is the most common leukemia diagnosed in the western hemisphere, and 16.5% to 66% of patients have reported using CAM. Most patients use spiritual/mind-body techniques and high doses of vitamins and herbs (most commonly polyphenols, including teas). We have reviewed the reported data on green tea and turmeric use in CLL patients.
Collapse
Affiliation(s)
- Erin Bange
- Center for CLL, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Colleen Timlin
- Center for CLL, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Charlene Kabel
- CLL Program, Leukemia Service, Section of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Jakub Svoboda
- Center for CLL, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Lindsey Roeker
- CLL Program, Leukemia Service, Section of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Anthony R Mato
- CLL Program, Leukemia Service, Section of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
| |
Collapse
|